Cytostatic treatment with irinotecan liposomal in a patient with advanced pancreatic adenocarcinoma

• Autorzy: , , Wojciech Rogowski
• Języki publikacji: EN

Abstrakty

EN

Pancreatic cancer is one of the most common malignant neoplasms with a short survival time and a low cure rate. This neoplasm progresses quickly, it is often diagnosed in the advanced stage, which means that systemic treatment regimens are not sufficiently effective. A case of 65-year-old patient with metastatic pancreatic cancer who underwent sequential chemotherapy with the use of liposomal irinotecan was presented.

Słowa kluczowe

EN

chemotherapy; liposomal irinotecan; pancreatic adenocarcinoma

• Wydawca: Medical Education
• Czasopismo: OncoReview
• Rocznik: 2021
• Tom: 11
• Numer: 2
• Strony: 40-43

Twórcy

autor

,

• 1. Department of Clinical Oncology, Chemotherapy, Clinical Research, Provincial Specialist Hospital in Slupsk. 2. Department of Daily Chemotherapy, Provincial Hospital in Koszalin

autor

Wojciech Rogowski

• 1. Department of Clinical Oncology, Chemotherapy, Clinical Research, Provincial Specialist Hospital in Slupsk. 2. Pomeranian Academy in Slupsk,

Bibliografia

• 1. Wojciechowska U, Didkowska J. Zachorowania i zgony na nowotwory złośliwe w Polsce. Krajowy Rejestr Nowotworów, Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie – Państwowy Instytut Badawczy (access: 1.02.2021).
• 2. Wang-Gillam A, Hubner RA, Siveke JT et al. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors. Eur J Cancer. 2019; 108: 78-87.
• 3. Taieb J, Abdallah R. How I treat pancreatic cancer. ESMO Open. 2020; 4(suppl 2): e000818. http://doi.org/10.1136/esmoopen-2020-000818.
• 4. Charakterystyka produktu leczniczego INN-Paklitaxel.
• 5. Conroy T, Desseigne F, Ychou M et al. FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer. N Engl J Med. 2011; 364: 1817-25. http://doi.org/10.1056/NEJMoa1011923.

• Typ dokumentu: article